ApoPharma
26
0
0
22
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 15/100
11.5%
3 terminated/withdrawn out of 26 trials
88.0%
+1.5% vs industry average
38%
10 trials in Phase 3/4
73%
16 of 22 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (26)
Focal Accumulation of Iron in Cerebral Regions in Early ALS (Amyotrophic Lateral Sclerosis) Patients
Role: collaborator
Conservative Iron Chelation as a Disease-modifying Strategy in Parkinson's Disease
Role: collaborator
Study of Parkinson's Early Stage With Deferiprone
Role: lead
Long-term Safety and Efficacy of Ferriprox® in Iron Overloaded Patients With Sickle Cell Disease or Other Anemias
Role: lead
Efficacy and Safety of Ferriprox® in Patients With Sickle Cell Disease or Other Anemias
Role: lead
Safety and Acceptability of Deferiprone Delayed Release Tablets in Patients With Systemic Iron Overload
Role: lead
Long-term Deferiprone Treatment in Patients With Pantothenate Kinase-Associated Neurodegeneration
Role: lead
Efficacy and Safety Study of Deferiprone in Patients With Pantothenate Kinase-associated Neurodegeneration (PKAN)
Role: lead
Evaluation of the Safety, Efficacy, and Pharmacokinetics of Intravenous Deferiprone in HIV-Positive Subjects
Role: lead
Pilot Study of the Pharmacokinetic Profile of Deferiprone Sustained-Release Formulation in Healthy Volunteers
Role: lead
Comparison of Deferiprone Delayed Release Tablets and Deferiprone Oral Solution in Healthy Volunteers
Role: lead
Comparison of Deferiprone Extended Release Tablets and Ferriprox Immediate Release Tablets in Healthy Volunteers
Role: lead
Efficacy Study in Removing Excess Iron From the Heart
Role: lead
Absorption, Metabolism, and Excretion of a Single Dose of Ferriprox® in Patients With Sickle Cell Disease
Role: lead
Study to Evaluate Apo805K1 in Subjects With Moderate to Severe Chronic Plaque Psoriasis
Role: lead
A Blinded, Placebo-Controlled Study of the Safety and Pharmacokinetics of Single Doses of Intravenous Deferiprone in Healthy Volunteers
Role: lead
Evaluation of Whether Deferiprone Affects QT Interval in Healthy Subjects
Role: lead
An Open-label, Non-randomized, Parallel Group Study in Subjects With Mild and Moderate Hepatic Insufficiency and Healthy Volunteers
Role: lead
An Open-label, Non-randomized, Parallel Group Study in Subjects With Mild, Moderate, Severe, or No Renal Impairment
Role: lead
Antiretroviral Activity and Pharmacokinetics of Deferiprone in Healthy Volunteers and Asymptomatic HIV-infected Subjects
Role: lead